Trial Profile
Phase III Randomized, Multi Center Study Of Sunitinib Malate (SU 011248) Or Capecitabine In Subjects With Advanced Breast Cancer Who Failed Both A Taxane And An Anthracycline Chemotherapy Regimen Or Failed With A Taxane And For Whom Further Anthracycline Therapy Is Not Indicated.
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 05 Oct 2021
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary) ; Capecitabine
- Indications Advanced breast cancer
- Focus Registrational; Therapeutic Use
- 27 Jul 2020 This trial is completed in UK (Global End Date: 28 Apr 2008), according to European Clinical Trials Database record.
- 28 Jul 2011 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 04 Apr 2011 Status changed from discontinued to active, no longer recruiting as reported by ClinicalTrials.gov.